A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
1 other identifier
interventional
56
3 countries
81
Brief Summary
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Feb 2025
81 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 5, 2025
CompletedFirst Submitted
Initial submission to the registry
February 7, 2025
CompletedFirst Posted
Study publicly available on registry
February 17, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 1, 2026
April 17, 2026
April 1, 2026
1.6 years
February 7, 2025
April 16, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Safety and tolerability as assessed by incidence of adverse events (AEs)
Day 1 to Week 12
Secondary Outcomes (2)
Percent participants with ≥30% reduction from baseline in UACR at Week 12
Day 1 to Week 12
Geometric mean plasma drug concentrations
Day 1 to Week 12
Study Arms (1)
MZE829
EXPERIMENTALCohort 1: Chronic kidney disease with concurrent diabetes Cohort 2: Chronic kidney disease without concurrent diabetes
Interventions
Eligibility Criteria
You may qualify if:
- APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2
- Chronic kidney disease with persistent albuminuria
You may not qualify if:
- Organ or bone marrow transplantation
- History of cancer within past 2 years, excepted for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer
- Conditions that may alter drug absorption, e.g., history of bariatric surgery
- Type I diabetes
- Pregnant or currently nursing
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (81)
Research Site
Decatur, Alabama, 35601, United States
Research Site
Huntsville, Alabama, 35805, United States
Research Site
Montgomery, Alabama, 36106, United States
Research Site
Montgomery, Alabama, 36117, United States
Research Site
Granada Hills, California, 91344, United States
Research Site
Bloomfield, Connecticut, 06112, United States
Research Site
Atlantis, Florida, 33462, United States
Research Site
Brandon, Florida, 33511, United States
Research Site
Brooksville, Florida, 34613, United States
Research Site
Hollywood, Florida, 33024, United States
Research Site
Melbourne, Florida, 32901, United States
Research Site
Miami Lakes, Florida, 33014, United States
Research Site
Orlando, Florida, 32822, United States
Research Site
Atlanta, Georgia, 30309, United States
Research Site
College Park, Georgia, 30349, United States
Research Site
Cordele, Georgia, 31015, United States
Research Site
Lithia Springs, Georgia, 30122, United States
Research Site
Macon, Georgia, 31210, United States
Research Site
Riverdale, Georgia, 30274, United States
Research Site
Riverdale, Georgia, 30296, United States
Research Site
Savannah, Georgia, 31406, United States
Research Site
Snellville, Georgia, 30078, United States
Research Site
Chicago, Illinois, 60616, United States
Research Site
Chicago, Illinois, 60643, United States
Research Site
Kansas City, Kansas, 66112, United States
Research Site
Bowling Green, Kentucky, 42101, United States
Research Site
Louisville, Kentucky, 40205, United States
Research Site
Arnold, Maryland, 21012, United States
Research Site
Lutherville, Maryland, 21093, United States
Research Site
Oxon Hill, Maryland, 20745, United States
Research Site
Dearborn, Michigan, 48126, United States
Research Site
Flint, Michigan, 48503, United States
Research Site
Pontiac, Michigan, 48341, United States
Research Site
Saint Joseph, Michigan, 49085, United States
Research Site
Shelby, Michigan, 48092, United States
Research Site
Minneapolis, Minnesota, 55404, United States
Research Site
Tupelo, Mississippi, 38801, United States
Research Site
City of Saint Peters, Missouri, 63376, United States
Research Site
St Louis, Missouri, 63103, United States
Research Site
Las Vegas, Nevada, 89107, United States
Research Site
Buffalo, New York, 14203, United States
Research Site
Laurelton, New York, 11413, United States
Research Site
Maspeth, New York, 11378, United States
Research Site
New York, New York, 10021, United States
Research Site
Newburgh, New York, 12550, United States
Research Site
Durham, North Carolina, 27708, United States
Research Site
Fayetteville, North Carolina, 28304, United States
Research Site
Greensboro, North Carolina, 27405, United States
Research Site
Shelby, North Carolina, 28150, United States
Research Site
Cincinnati, Ohio, 45267, United States
Research Site
Cleveland, Ohio, 44106, United States
Research Site
Cleveland, Ohio, 44195, United States
Research Site
Columbus, Ohio, 43215, United States
Research Site
Ardmore, Oklahoma, 73401, United States
Research Site
Philadelphia, Pennsylvania, 19104, United States
Research Site
Philadelphia, Pennsylvania, 19107, United States
Research Site
Upland, Pennsylvania, 19013, United States
Research Site
Columbia, South Carolina, 29203, United States
Research Site
Spartanburg, South Carolina, 29302, United States
Research Site
Spartanburg, South Carolina, 29306, United States
Research Site
Chattanooga, Tennessee, 37404, United States
Research Site
Dallas, Texas, 75230, United States
Research Site
Dallas, Texas, 75246, United States
Research Site
Greenville, Texas, 75402, United States
Research Site
Houston, Texas, 77030, United States
Research Site
Houston, Texas, 77054, United States
Research Site
Houston, Texas, 77099, United States
Research Site
McKinney, Texas, 75069, United States
Research Site
San Antonio, Texas, 78251, United States
Research Site
Shenandoah, Texas, 77384, United States
Research Site
Sherman, Texas, 75092, United States
Research Site
Norfolk, Virginia, 23504, United States
Research Site
Créteil, 94010, France
Research Site
Lyon, 69347, France
Research Site
Paris, 75015, France
Research Site
Paris, 75020, France
Research Site
Saint-Ouen, 93400, France
Research Site
Leicester, LE5 4PW, United Kingdom
Research Site
London, NW3 2QG, United Kingdom
Research Site
London, SE19RT, United Kingdom
Research Site
London, SE59RS, United Kingdom
Study Officials
- STUDY DIRECTOR
Medical Director
Maze Therapeutics
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 7, 2025
First Posted
February 17, 2025
Study Start
February 5, 2025
Primary Completion (Estimated)
September 1, 2026
Study Completion (Estimated)
September 1, 2026
Last Updated
April 17, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share